RLYB — Rallybio Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1739410 ·
Last close
$16.62
Market Cap
$88.26M
52W High
$17.57
52W Low
$3.67
ADV30
10,320
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,653,000 | 43,665,000 | 98,063,000 | 92,849,000 | 3,567,000 |
| Mar 2026 | 212,000 | — | -8,733,000 | -8,278,000 | 54,472,000 | 41,299,000 | 4,195,000 |
| Dec 2025 | 222,000 | — | -6,412,000 | -5,852,000 | 62,261,000 | 31,374,000 | 4,305,000 |
| Sep 2025 | 212,000 | — | -6,925,000 | 16,016,000 | 67,661,000 | 32,122,000 | 4,627,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$26,712,000
Investing CF
$56,552,000
Financing CF
$140,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-266,611,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-27,723,000
Pretax Income TTM
$46,875,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$646,000
EBITDA
$-25,380,000
Free Cash Flow
$-14,290,375
Enterprise Value
$-3,234,329
Total Cash
$92,849,000
Total Debt
$0
Shares Out
5,310,499
Trailing EPS
$7.99
Book Value
$17.81
ROE
64.9%
ROA
-21.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 858,000 | -33,064,000 | -8,978,000 | 62,261,000 | 4,305,000 | 57,956,000 | -29,813,000 |
| Dec 2024 | 636,000 | -60,496,000 | -57,775,000 | 68,108,000 | 6,454,000 | 61,654,000 | -49,282,000 |
| Dec 2023 | 0 | -78,932,000 | -74,564,000 | 115,620,000 | 9,436,000 | 106,184,000 | -60,265,000 |
| Dec 2022 | 0 | -67,884,000 | -66,654,000 | 180,435,000 | 11,118,000 | 169,317,000 | -57,284,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$299,000
NetIncome TTM
$-48,210,000
OpCashFlow TTM
$0
Assets (Latest)
$68,108,000
Forward EPS
$-5.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. | $87.61M | $0.76 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $86.71M | $0.68 | — |
| ACRV | Acrivon Therapeutics, Inc. | $89.99M | $2.10 | — |
| BGM | BGM Group Ltd. | $91.35M | $0.24 | — |
News headlines (Yahoo Finance, 1h cache)
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
2026-06-01 16:26 · Yahoo
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
2026-06-01 12:00 · Yahoo
RallyBio tries again for reverse merger, this time with Avenzo
2026-06-01 15:03 · Yahoo
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
2026-06-24 18:15 · Yahoo
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
2026-06-22 15:40 · Yahoo
Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026
2026-02-04 15:05 · Yahoo
Rallybio to acquire Candid Therapeutics
2026-03-03 12:29 · Yahoo
Candid, in a reverse merger with RallyBio, to go public
2026-03-02 11:05 · Yahoo
Stock Splits Matter: What’s Coming Up This Month?
2026-02-04 15:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.